Biophytis Targets Mobility Restoration in Patients with Obesity

Core Viewpoint - Biophytis is positioning itself as a leader in addressing the muscle mass loss associated with GLP-1 therapies for obesity, focusing on the quality of weight loss and mobility restoration for patients [1][4]. Group 1: Company Overview - Biophytis SA is a clinical-stage biotechnology company focused on developing treatments for age-related diseases, with its lead drug candidate BIO101 targeting muscular diseases and metabolic disorders [5]. - The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, and Brazil, and its shares are listed on Euronext Growth Paris and the OTC market [5]. Group 2: Product Development - The drug candidate BIO101, when combined with GLP-1 therapies, has shown preclinical results indicating it enables high-quality weight loss while improving muscle function and strength [2]. - Biophytis is specifically targeting patients with obesity who are treated with GLP-1 therapies, addressing a significant unmet medical need [2][3]. Group 3: Market Potential - The global obesity market is projected to reach $100 billion by 2030, highlighting the substantial market opportunity for Biophytis [3]. - A significant 96% of patients with obesity experience impairment in muscle strength, underscoring the need for solutions that preserve muscle mass during weight loss [3]. Group 4: Competitive Landscape - Biophytis is the only company focusing on muscle quality and mobility restoration in the context of obesity treatment, differentiating itself from competitors [3]. - The acquisition of Versanis by Lilly for nearly$ 2 billion in 2023 indicates a growing recognition in the pharmaceutical industry of the need to combine GLP-1s with other treatments to mitigate muscle mass loss [3].